Victory Capital Management Inc. Has $75.95 Million Position in United Therapeutics Corporation (NASDAQ:UTHR)

Victory Capital Management Inc. lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 27.4% during the 1st quarter, Holdings Channel reports. The firm owned 246,359 shares of the biotechnology company’s stock after purchasing an additional 52,951 shares during the quarter. Victory Capital Management Inc.’s holdings in United Therapeutics were worth $75,945,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Trail Ridge Investment Advisors LLC boosted its position in shares of United Therapeutics by 4.0% in the 1st quarter. Trail Ridge Investment Advisors LLC now owns 2,212 shares of the biotechnology company’s stock worth $682,000 after purchasing an additional 85 shares in the last quarter. Hohimer Wealth Management LLC boosted its position in United Therapeutics by 0.3% during the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company’s stock worth $3,900,000 after acquiring an additional 37 shares during the last quarter. Florida Financial Advisors LLC increased its stake in United Therapeutics by 53.3% during the 1st quarter. Florida Financial Advisors LLC now owns 1,260 shares of the biotechnology company’s stock worth $388,000 after buying an additional 438 shares during the period. Aurora Investment Counsel purchased a new position in shares of United Therapeutics in the 1st quarter valued at $2,030,000. Finally, MQS Management LLC purchased a new position in shares of United Therapeutics in the 1st quarter valued at about $273,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 12,000 shares of the business’s stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the transaction, the chief financial officer directly owned 8,118 shares in the company, valued at $2,641,353.66. The trade was a 59.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Raymond Dwek sold 3,000 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $285.57, for a total transaction of $856,710.00. Following the completion of the transaction, the director directly owned 1,750 shares of the company’s stock, valued at approximately $499,747.50. The trade was a 63.16% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 73,681 shares of company stock valued at $22,140,089. 10.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on UTHR shares. Bank of America reduced their price target on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating for the company in a report on Wednesday, June 11th. UBS Group lowered their target price on United Therapeutics from $410.00 to $385.00 and set a “buy” rating for the company in a research note on Monday, June 30th. JPMorgan Chase & Co. lowered their price target on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research note on Tuesday, July 8th. Morgan Stanley dropped their price target on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. Finally, Wall Street Zen lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $383.08.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $297.33 on Friday. The stock’s 50 day simple moving average is $300.61 and its two-hundred day simple moving average is $318.55. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $417.82. The company has a market cap of $13.41 billion, a price-to-earnings ratio of 11.86, a PEG ratio of 6.52 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analysts’ expectations of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The company’s revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the firm posted $6.17 earnings per share. As a group, analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.